Monitoring factor VIII (FVIII) activity has traditionally been complicated by discrepancies
between assays for the various sorts of FVIII molecules. The advent of novel nonfactor …

Epidemiological and laboratory studies performed in the last decades have changed our
understanding of coagulopathy in cirrhosis, from a condition at increased risk of …

Cardiovascular diseases (CVDs) are currently the leading cause of death worldwide.
Therefore, there is interest in the search for cardiovascular risk markers that contribute to the …

Coronavirus disease 2019 (COVID-19) is associated with marked albeit variable hemostasis
disturbances and high thrombotic risk [1]. Measurement of plasma D-dimers levels has been …

Introduction Contraceptives containing ethinylestradiol (EE) induce changes in the
coagulation system and are associated with a risk of venous thromboembolism. However …

Abstract Background Thrombin generation assays (TGAs) performed with calibrated
automated thrombography (CAT) in the presence of thrombomodulin (TM) indicate plasma …

Introduction The bispecific antibody, emicizumab, is a prophylactic therapy used for the
treatment of haemophilia A (HA). Patients may require additional replacement factor VIII …

Background Monitoring of anticoagulant activity of direct oral anticoagulants (DOACs) can
be necessary in special situations. DOAC plasma levels have a high inter‐and …

This data article accompanies the manuscript entitled:“Prothrombotic Disturbances of
hemostasis of Patients with Severe COVID-19: a Prospective Longitudinal Observational …

Background The thrombin generation (TG) assay, which measures global coagulation, has
mainly been used as a research tool to investigate thrombotic and bleeding disorders …